8-K: NewAmsterdam Pharma Announces Positive Phase 3 Trial Results for Obicetrapib at AHA Scientific Sessions

NewAmsterdam Pharma released additional positive data from its Phase 3 BROOKLYN trial, showing significant reductions in LDL-C and other key lipid markers with obicetrapib.

Summary

• NewAmsterdam Pharma announced additional data from its Phase 3 BROOKLYN clinical trial for obicetrapib, a drug aimed at lowering cholesterol.
• The trial met its primary endpoint, showing a 36.3% reduction in LDL-C compared to placebo after 84 days, and this reduction was sustained at 41.5% after 365 days.
• The study also met several secondary endpoints, including significant reductions in lipoprotein(a) (Lp(a)), apolipoprotein B (ApoB), and non-HDL-C, and an increase in HDL-C.
• Obicetrapib was well-tolerated, with safety results comparable to placebo and no increase in blood pressure.
• The treatment discontinuation rate was lower in the obicetrapib arm (7.6%) compared to the placebo arm (14.4%).
• The trial involved 354 patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C was not adequately controlled despite being on maximally tolerated lipid-lowering therapy.
• The mean baseline LDL-C for patients in the obicetrapib arm was 123 mg/dL, with 79% on high-intensity statins, 54% on ezetimibe, and 14% on PCSK9 inhibitors.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with significant reductions in key lipid markers and a good safety profile, suggesting a strong potential for the drug. The management commentary is also positive, and the company is moving towards commercialization. However, there are still risks associated with regulatory approvals and commercialization.

Positives

• Obicetrapib showed significant reductions in LDL-C and other key lipid markers.
• The drug was well-tolerated with a safety profile comparable to placebo.
• The treatment discontinuation rate was lower in the obicetrapib arm.
• The trial met its primary and several secondary endpoints with statistical significance.
• The results are consistent with previous clinical trials of obicetrapib.

Negatives

• There was a slight increase in new diabetes or worsening glycemic control in both the placebo and obicetrapib groups, with 22.0% and 20.5% respectively.
• There were some cardiovascular events reported in both the placebo and obicetrapib groups, with 4.2% and 2.6% respectively.

Risks

• The company faces risks related to the approval of its product candidate and the timing of regulatory milestones.
• There are risks associated with commercializing the product candidate.
• The company's ability to negotiate and enter into definitive agreements on favorable terms is a risk.
• The impact of competing product candidates on the company's business is a risk.
• Intellectual property related claims are a risk.
• The company's ability to attract and retain qualified personnel is a risk.
• The ability to continue to source raw materials for its product candidate is a risk.
• Global economic and political conditions, including the Russia-Ukraine and Israel-Hamas conflicts, pose risks.

Future Outlook

The company expects to report topline data from the TANDEM and BROADWAY studies in the fourth quarter of 2024 and is progressing towards potential regulatory approvals and commercialization of obicetrapib.

Management Comments

• Stephen Nicholls stated that the data underscores obicetrapib's potential to significantly reduce LDL-C, Lp(a), and LDL particles in HeFH patients.
• Michael Davidson believes that obicetrapib has the potential to meaningfully reduce LDL-C and improve other CVD risk parameters.
• John Kastelein is encouraged by the lipidand lipoprotein-lowering capabilities of obicetrapib in a difficult-to-treat patient population.

Industry Context

This announcement is significant in the context of the ongoing need for effective treatments for cardiovascular disease, particularly for patients with HeFH who do not achieve adequate LDL-C control with existing therapies. The positive results for obicetrapib position it as a potential new option in this space.

Comparison to Industry Standards

• The LDL-C reduction of 36.3% at day 84 and 41.5% at day 365 is competitive with other novel lipid-lowering therapies, such as PCSK9 inhibitors, which typically show LDL-C reductions in the range of 50-60% when added to statin therapy.
• The significant reduction in Lp(a) is notable, as many existing therapies do not effectively target this risk factor. Companies like Amgen and Novartis are also developing therapies targeting Lp(a), but the results from NewAmsterdam are promising.
• The safety profile of obicetrapib, being comparable to placebo, is a positive differentiator, as some other lipid-lowering drugs have been associated with side effects.
• The trial results are comparable to other CETP inhibitors in development, but obicetrapib's tolerability and efficacy profile may position it favorably.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with HeFH may benefit from a new treatment option.
• Physicians may have a new tool to address unmet needs in lipid management.
• The company's employees may be positively impacted by the progress of the drug development.

Next Steps

• The company will continue to analyze the data from the BROOKLYN trial.
• Topline data from the TANDEM and BROADWAY studies are expected in the fourth quarter of 2024.
• The company will pursue regulatory approvals for obicetrapib.
• The company will continue to work towards commercialization of obicetrapib.

Key Dates

Keywords

Obicetrapib, Heterozygous Familial Hypercholesterolemia, HeFH, LDL-C, Lipid-lowering, Cardiovascular Disease, AHA Scientific Sessions, Clinical Trial, Cholesterol, Lp(a), ApoB, HDL-C